Statistics for A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
Total visits
| views | |
|---|---|
| A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis | 48 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| Coelho-2020-A-phase-ii-open-label-extension-stu.pdf(legacy) | 14 |
| Coelho-2020-A-phase-ii-open-label-extension-stu.pdf | 4 |
Top country views
| views | |
|---|---|
| United States | 17 |
| China | 12 |
| Germany | 4 |
| Australia | 3 |
| Latvia | 2 |
| Russia | 2 |
| Argentina | 1 |
| Canada | 1 |
| United Kingdom | 1 |
| Israel | 1 |
| India | 1 |
| Norway | 1 |
| Romania | 1 |
| Singapore | 1 |